Biotechnological treatment of microalgae enhances growth performance, hepatic carbohydrate metabolism and intestinal physiology in gilthead seabream (Sparus aurata) juveniles close to commercial size

The aim of this work was to evaluate the effects on growth performance, intermediary metabolism and welfare inclusion two commercial microalgae-based ingredients called LB-ChromaBream (LB-CB) LB-ChromaBream-plus (LB-CBplus) in diet gilthead seabream (Sparus aurata) close size. For purpose, fish ~182 g initial body mass were fed satiety (ad libitum) for 41 days with three different diets: (i) CONTROL (CTRL), a commercial-like formulation; (ii) LB-CB diet, 10 % microalgal product; (iii) LB-CBplus same product but enzymatically hydrolysed increase bioavailability nutrients. results obtained show that use these products leads an overall improvement productive parameters terms (15 SGR) feed efficiency (11 %), as well significant reduction circulating cortisol diet. Observations plasma liver metabolites, particularly hepatic metabolic enzymes, collectively indicate microalgae supplementation lead better carbohydrates source energy other tissues, potentially sparing triglycerides within tissue, channelling fuels growth. Finally, specimens supplemented diets experienced substantial intestinal health, achieved by longer intestines, higher transepithelial resistance apparent permeability measured electrophysiological methods, especially those LB-CBplus, which could explain performance improving nutrient assimilation. In conclusion, study shows experimental feeds, one containing biotechnologically treated microalgae, are suitable some important indicators physiological condition seabream, thus revealing potential their new functional feeds species at advanced stage production cycle.